NCT02545959View on ClinicalTrials.gov

Intrathecal Rituximab in Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 22, 2019

Study Completion Date

September 2, 2019

Conditions
Multiple Sclerosis, Chronic ProgressiveNervous System Diseases
Interventions
DRUG

Rituximab IT

CSF injection of intrathecal rituximab (20mg)

DRUG

methylprednisolone IV

blood infusion of methylprednisolone IV (120mg)

DRUG

Rituximab IV

Blood infusion of rituximab (375mg/m2)

Trial Locations (1)

64000

Centre hospitalier F. Mitterrand (CH Pau), Pau

All Listed Sponsors
collaborator

University Hospital, Bordeaux

OTHER

lead

Centre Hospitalier de PAU

OTHER

NCT02545959 - Intrathecal Rituximab in Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter